{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T07:59:58Z","timestamp":1789718398208,"version":"4.0.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"vor","delay-in-days":2423,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1007\/s13311-016-0472-0","type":"journal-article","created":{"date-parts":[[2016,9,6]],"date-time":"2016-09-06T12:58:37Z","timestamp":1473166717000},"page":"154-160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Strength Testing in Motor Neuron Diseases"],"prefix":"10.1016","volume":"14","author":[{"given":"Jeremy M.","family":"Shefner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-016-0472-0_bib1","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJM191210241671701","article-title":"Muscle training in the treatment of infantile paralysis","volume":"167","author":"Wright","year":"1912","journal-title":"Boston Med Surg J"},{"key":"10.1007\/s13311-016-0472-0_bib2","series-title":"Aids to the examination of the peripheral nervous system. War Memorandum","author":"Council MR","year":"1943"},{"key":"10.1007\/s13311-016-0472-0_bib3","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJM199403033300901","article-title":"A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS\/Riluzole Study Group","volume":"330","author":"Bensimon","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-016-0472-0_bib4","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/S0140-6736(96)91680-3","article-title":"Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis\/Riluzole Study Group II","volume":"347","author":"Lacomblez","year":"1996","journal-title":"Lancet"},{"key":"10.1007\/s13311-016-0472-0_bib5","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/sj.clpt.6100382","article-title":"An association study of riluzole serum concentration and survival and disease progression in patients with ALS","volume":"83","author":"Groeneveld","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1007\/s13311-016-0472-0_bib6","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1474-4422(07)70270-3","article-title":"Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial","volume":"6","author":"Gordon","year":"2007","journal-title":"Lancet Neurol"},{"issue":"8","key":"10.1007\/s13311-016-0472-0_bib7","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1212\/01.wnl.0000269676.07319.09","article-title":"Phase II\/III randomized trial of TCH346 in patients with ALS","volume":"69","author":"Miller","year":"2007","journal-title":"Neurology"},{"key":"10.1007\/s13311-016-0472-0_bib8","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1212\/WNL.0b013e3182020332","article-title":"Randomized, double-blind, placebo-controlled trial of hydroxyurea in spinal muscular atrophy","volume":"75","author":"Chen","year":"2010","journal-title":"Neurology"},{"key":"10.1007\/s13311-016-0472-0_bib9","unstructured":"Young SD, Montes J, Kramer SS, et al. Six-minute walk test is reliable and valid in spinal muscular atrophy. Muscle Nerve 2016 Mar 25."},{"key":"10.1007\/s13311-016-0472-0_bib10","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.nmd.2012.06.352","article-title":"Change in muscle strength over time in spinal muscular atrophy types II and III. A long-term follow-up study","volume":"22","author":"Werlauff","year":"2012","journal-title":"Neuromuscul Disord"},{"key":"10.1007\/s13311-016-0472-0_bib11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1212\/01.wnl.0000249142.82285.d6","article-title":"Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy","volume":"68","author":"Mercuri","year":"2007","journal-title":"Neurology"},{"key":"10.1007\/s13311-016-0472-0_bib12","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0022-510X(01)00632-3","article-title":"A placebo-controlled trial of gabapentin in spinal muscular atrophy","volume":"191","author":"Miller","year":"2001","journal-title":"J Neurol Sci"},{"key":"10.1007\/s13311-016-0472-0_bib13","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1212\/WNL.0b013e318295d766","article-title":"Pilot trial of clenbuterol in spinal and bulbar muscular atrophy","volume":"80","author":"Querin","year":"2013","journal-title":"Neurology"},{"key":"10.1007\/s13311-016-0472-0_bib14","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1212\/01.WNL.0000095961.66830.03","article-title":"A comparison of muscle strength testing techniques in amyotrophic lateral sclerosis","volume":"61","author":"Great Lakes ALSSG","year":"2003","journal-title":"Neurology"},{"key":"10.1007\/s13311-016-0472-0_bib15","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/BF00313939","article-title":"Measuring muscle strength","volume":"231","author":"van der Ploeg","year":"1984","journal-title":"J Neurol"},{"issue":"Suppl","key":"10.1007\/s13311-016-0472-0_bib16","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/0022-510X(96)00108-6","article-title":"A comparison of three measures of disease progression in ALS","volume":"139","author":"Andres","year":"1996","journal-title":"J Neurol Sci"},{"key":"10.1007\/s13311-016-0472-0_bib17","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1136\/jnnp.46.11.1006","article-title":"The measurement of strength in patients with peripheral neuromuscular disorders","volume":"46","author":"Wiles","year":"1983","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-016-0472-0_bib18","doi-asserted-by":"crossref","unstructured":"Andres P, W H, Finison L, Conlon T, Felmus M, Munsat T. Quantitative motor assessment in amyotrophic lateral sclerosis. Neurology 1986;36:937\u2013941","DOI":"10.1212\/WNL.36.7.937"},{"key":"10.1007\/s13311-016-0472-0_bib19","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/mus.23516","article-title":"Developing normalized strength scores for neuromuscular research","volume":"47","author":"Andres","year":"2012","journal-title":"Muscle Nerve"},{"key":"10.1007\/s13311-016-0472-0_bib20","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1212\/WNL.38.3.405","article-title":"Use of composite scores (megascores) to measure deficit in amyotrophic lateral sclerosis","volume":"38","author":"Andres","year":"1988","journal-title":"Neurology"},{"key":"10.1007\/s13311-016-0472-0_bib21","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0733-8619(18)30938-1","article-title":"Quantitative assessment of neuromuscular deficit in ALS","volume":"5","author":"Andres","year":"1987","journal-title":"Neurol Clin"},{"key":"10.1007\/s13311-016-0472-0_bib22","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1212\/WNL.38.3.409","article-title":"The natural history of motoneuron loss in amyotrophic lateral sclerosis","volume":"38","author":"Munsat","year":"1988","journal-title":"Neurology"},{"key":"10.1007\/s13311-016-0472-0_bib23","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/ana.20903","article-title":"Trial of celecoxib in amyotrophic lateral sclerosis","volume":"60","author":"Cudkowicz","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-016-0472-0_bib24","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1212\/WNL.61.4.456","article-title":"A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis","volume":"61","author":"Cudkowicz","year":"2003","journal-title":"Neurology"},{"key":"10.1007\/s13311-016-0472-0_bib25","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3109\/17482960903307805","article-title":"A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis","volume":"11","author":"Pascuzzi","year":"2010","journal-title":"Amyotroph Lateral Scler"},{"key":"10.1007\/s13311-016-0472-0_bib26","first-page":"1063","article-title":"Relationship between two measures of upper extremity strength: manual muscle test compared to hand-held myometry","volume":"73","author":"Schwartz","year":"1992","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1007\/s13311-016-0472-0_bib27","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/jnnp.53.5.384","article-title":"Laboratory testing of muscle function in the management of neuromuscular disease","volume":"53","author":"Wiles","year":"1990","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-016-0472-0_bib28","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1136\/jnnp.54.3.248","article-title":"The \"make\/break test\" as a diagnostic tool in functional weakness","volume":"54","author":"van der Ploeg","year":"1991","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-016-0472-0_bib29","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S1474-4422(10)70068-5","article-title":"Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial","volume":"9","author":"Aggarwal","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-016-0472-0_bib30","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1474-4422(14)70222-4","article-title":"Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial","volume":"13","author":"Cudkowicz","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-016-0472-0_bib31","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S1474-4422(13)70221-7","article-title":"Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial","volume":"12","author":"Cudkowicz","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-016-0472-0_bib32","doi-asserted-by":"crossref","first-page":"426","DOI":"10.3109\/21678421.2016.1148169","article-title":"A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis","volume":"17","author":"Shefner","year":"2016","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"10.1007\/s13311-016-0472-0_bib33","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3109\/21678421.2013.822517","article-title":"A study to evaluate safety and tolerability of repeated doses of tirasemtiv in patients with amyotrophic lateral sclerosis","volume":"14","author":"Shefner","year":"2013","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"10.1007\/s13311-016-0472-0_bib34","doi-asserted-by":"crossref","first-page":"582","DOI":"10.3109\/21678421.2013.817587","article-title":"The relationship between tirasemtiv serum concentration and functional outcomes in patients with ALS","volume":"14","author":"Shefner","year":"2013","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"10.1007\/s13311-016-0472-0_bib35","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3109\/17482968.2012.684214","article-title":"Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosis","volume":"13","author":"Shefner","year":"2012","journal-title":"Amyotroph Lateral Scler"},{"key":"10.1007\/s13311-016-0472-0_bib36","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1212\/WNL.0000000000002941","article-title":"Quantitative strength testing in ALS clinical trials","volume":"87","author":"Shefner","year":"2016","journal-title":"Neurology"},{"key":"10.1007\/s13311-016-0472-0_bib37","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1212\/01.WNL.0000144345.49510.4E","article-title":"Functional outcome measures as clinical trial endpoints in ALS","volume":"63","author":"Traynor","year":"2004","journal-title":"Neurology"},{"key":"10.1007\/s13311-016-0472-0_bib38","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3109\/17482968.2012.688837","article-title":"Electrical impedance myography as a biomarker to assess ALS progression","volume":"13","author":"Rutkove","year":"2012","journal-title":"Amyotroph Lateral Scler"},{"key":"10.1007\/s13311-016-0472-0_bib39","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1212\/01.wnl.0000231139.26253.d0","article-title":"Valproate may improve strength and function in patients with type III\/IV spinal muscle atrophy","volume":"67","author":"Weihl","year":"2006","journal-title":"Neurology"},{"key":"10.1007\/s13311-016-0472-0_bib40","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/mus.23904","article-title":"SMA valiant trial: a prospective, double-blind, placebo-controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy","volume":"49","author":"Kissel","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.1007\/s13311-016-0472-0_bib41","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.nmd.2013.10.011","article-title":"Somatropin treatment of spinal muscular atrophy: a placebo-controlled, double-blind crossover pilot study","volume":"24","author":"Kirschner","year":"2014","journal-title":"Neuromuscul Disord"},{"key":"10.1007\/s13311-016-0472-0_bib42","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/mus.10166","article-title":"Reliability of hand-held dynamometry in spinal muscular atrophy","volume":"26","author":"Merlini","year":"2002","journal-title":"Muscle Nerve"},{"key":"10.1007\/s13311-016-0472-0_bib43","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/mus.22253","article-title":"Validation of a new strength measurement device for amyotrophic lateral sclerosis clinical trials","volume":"45","author":"Andres","year":"2012","journal-title":"Muscle Nerve"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-016-0472-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-016-0472-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923015210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923015210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-016-0472-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:06:22Z","timestamp":1761807982000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923015210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S1878747923015210"],"URL":"https:\/\/doi.org\/10.1007\/s13311-016-0472-0","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Strength Testing in Motor Neuron Diseases","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-016-0472-0","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}